M E D I C A L C O N T R AC T M A N U FAC T U R E R A U T O - I N J E C T O R H O U S I N G • Excellent chemical and wear resistance • Excellent impact resistance • Specific color matching based on customer’s needs • Outstanding durability to extend product life • Customized a chemically resistant formulation to offer an impact-modified alternative to traditional competitors in the market • Provided technical support for material selection, part & tool design, and process development to accelerate commercialization • Delivered custom color matching to meet all key requirements Custom Trilliant™ HC Healthcare Thermoplastic KEY REQUIREMENTS WHY AVIENT? https://www.avient.com/products/engineered-polymer-formulations/chemical-corrosion-resistant-formulations/trilliant-hc-healthcare-thermoplastics

O RT H O P E D I C PA RT S M A N U FAC T U R E R O R T H O P E D I C S O L E I N S E R T • A super soft TPE (

MEDICAL DEVICE MA NUFAC TURER S T E T H O S C O P E S • Provide a silicone paste colorant dispersion for liquid silicone rubber (LSR) to use in stethoscope ear tips • Create a custom-colored vinyl plastisol formulation for stethoscope tubing • Harmonize color across materials to meet specific process and performance requirements • Deliver effective communication and cross-functional collaboration • Offered dependable silicone paste colorants that allowed for comfort and easy sterilization • Provided a colored vinyl plastisol to reduce tackiness and support product longevity • Collaborated internally to align all materials and provide color consistency across components • Supported fast color changes and met quality specifications through constant communication and technical expertise Silcopas Silicone Paste Colorants and CORE Vinyl Plastisols for Healthcare KEY REQUIREMENTS WHY AVIENT? https://www.avient.com/products/vinyl-formulations/vinyl-plastisols-organosols/core-vinyl-plastisols-healthcare https://www.avient.com/products/polymer-colorants/colorant-dispersions/colorants-liquid-silicone-rubber Slide 1: Medical device manufacturer

PRODUCT BULLETIN Stan-Tone™ HC Plus Silicone Dispersions for Healthcare Stan-Tone™ HC Plus Silicone Dispersions leverage silicone’s biocompatibility, conformability, and durability for healthcare applications. By meeting stringent USP Class VI biocompatibility standards, Stan-Tone HC Plus offers pre-tested solutions that speed up development time, decrease risk, and satisfy healthcare industry material requirements. KEY CHARACTERISTICS • Meets USP Class VI standards • Biocompatible • Provides lightfastness, chemical resistance, and heat stability • Available in standard single pigment or custom multi-pigment colors • LSR and HCR options available TARGET APPLICATIONS Stan-Tone HC Plus silicone dispersions are suitable for a variety of healthcare applications including: • Catheters and medical tubing • Medical and surgical equipment • Labware and diagnostic devices • Specialty medical devices and wearables Product Code Pigment Type % Pigment (approx.)

PRODUCT BULLETIN Stan-Tone™ HC Plus Silicone Dispersions for Healthcare Stan-Tone™ HC Plus Silicone Dispersions leverage silicone’s biocompatibility, conformability, and durability for healthcare applications. By meeting stringent USP Class VI biocompatibility standards, Stan-Tone HC Plus offers pre-tested solutions that speed up development time, decrease risk, and satisfy healthcare industry material requirements. KEY CHARACTERISTICS • Meets USP Class VI standards • Biocompatible • Provides lightfastness, chemical resistance, and heat stability • Available in standard single pigment or custom multi-pigment colors • LSR and HCR options available TARGET APPLICATIONS Stan-Tone HC Plus silicone dispersions are suitable for a variety of healthcare applications including: • Catheters and medical tubing • Medical and surgical equipment • Labware and diagnostic devices • Specialty medical devices and wearables Product Code Pigment Type % Pigment (approx.)

We partner with Brand Owners / OEMs, processors and assemblers to enable their goals in applications like packaging, healthcare, consumer goods, transportation, wire & cable, building & construction and textiles. $600 $592 2021 2022 $3.02 $3.04 2021 2022 FULL YEAR 2022 PERFORMANCE ( T O TA L C O M PA N Y P R O F O R M A ) 19 Sales Adjusted EBITDA $3,712 $3,653 2021 2022 - 2% Adjusted EPS - 1% + 1% (in millions) (in millions) (+ 4% excluding FX) (+ 5% excluding FX) (+ 9% excluding FX) FULL YEAR 2022 SEGMENT PERFORMANCE 20 CAI $2,402 $2,355 Sales ($ in millions) $409 $402 EBITDA SEM Pro Forma $1,308 $1,300 Sales $278 $272 EBITDA (+ 4% excluding FX) - 2% - 1% (+ 5% excluding FX) - 2% (+ 4% excluding FX) - 2% (+ 2% excluding FX) PRO FORMA FULL YEAR EPS BRIDGE 21 Pro Forma 2021 Adjusted EPS 3.02$ Foreign Currency (0.23) Russia Import Sales (0.07) Outdoor High Performance (0.13) Color, Additives and Inks 0.18 Specialty Engineered Materials 0.24 Corporate Costs / Other 0.03 Pro Forma 2022 Adjusted EPS 3.04$ FULL YEAR EBITDA BRIDGE ( P R O F O R M A T O TA L C O M PA N Y ) 22 $ millions CAI: Price / Mix 247 Inflation (176) SEM: Price / Mix 121 Inflation (77) Net Price Benefit 115 Wage and Energy Inflation (47) Clariant Color Integration Synergies 23 Incentives, Other Employee Costs 43 FX (34) Full Year 2022 $592 Adjusted EBITDA Full Year 2021 $ 600 Demand (99) Russia Import Sales (9) • Demand primarily impacted by China lockdowns, 4th quarter industrywide destocking and declining consumer sentiment • Pricing outpaced inflation of raw materials, wages and energy 2 0 2 3 G U I D A N C E $125 $530 Q1 FY $0.55 $2.40 Q1 FY 2023 GUIDANCE 24 Sales Adjusted EBITDA $845 $3,450 Q1 FY Adjusted EPS (in millions) (in millions) CA SH FLOW / BALANCE SHEET 25 • IT investment to further integrate acquired businesses and capture operational efficiencies • Restructuring actions to streamline operations and improve profitability, primarily in Europe ($ millions) 2023E Cash Flow from Operating Activities 350$ Less: Run-Rate CapEx (110) CapEx for IT System Upgrade (25) CapEx for Restructuring (15) Total CapEx (150) Free Cash Flow 200$ Adjusted EBITDA 530$ Net Debt / Adjusted EBITDA 2.9x K E Y G R O W T H D R I V E R S A N D T R A N S F O R M E D P O R T F O L I O GROW TH DR IVER S: PROV EN SUCC ESS 27 (1) Pro forma for the acquisition of Avient Protective Materials (APM) COMPOSITES $51 $84 $212 $668 2016 2018 2020 2022 Long Term Growth Rate 10% Organic CAGR 10% HEALTHCARE $108 $113 $231 $293 2016 2018 2020 2022 Long Term Growth Rate 8-10% Organic CAGR 11% ASIA/EMERGING REGIONS $265 $358 $726 $830 2016 2018 2020 2022 Long Term Growth Rate 5% Organic CAGR 12% $340 $455 $790 2016 2018 2020 2022 $1,175 SUSTAINABLE SOLUTIONS Long Term Growth Rate 8-12% Organic CAGR 11% (1) (1)(1) (Sales in $ millions) #1 Color Formulator Dyneema® - World’s Strongest Fiber™ #1 in Composites applications for outdoor high performance #1 in Performance Inks Customized solutions 140+ PhDs on staff Rapid development of innovative products Extensive patent (2,500+) portfolio 33% Vitality Index Better-positioned toward stable, high-growth end markets Consumer, packaging, healthcare and defense comprise nearly 60% of sales Agnostic to raw materials, helping all customers achieve their goals Broad portfolio of diversified sustainable solutions 90%+ of our innovation pipeline invested in sustainable solutions Long-term growth rate well above GDP with expectations of 8-12% L E V E R AG I N G O U R T R A N S F OR M E D PO RT F O L I O 28 Healthcare 8% Packaging 24% Consumer 20% Building & Construction 10% Industrial 15% Transportation 9% Energy 4% Telecom. 4% 2022 PF $3.65B sales Defense 6% Leading Positions Sustainable SolutionsDiversified IndustriesSpecialty Formulator (1) 2022 Pro forma for the acquisition of Avient Protective Materials (2) 2020 Pro forma for the acquisition of Clariant Color (1)(2) (1) $340M $455M $790M 2016 2018 2020PF 2022PF $1,175M P E E R C O M PA R I S O N S AV I E N T I S A S SE T L I G H T Capex / Revenue 2023E (%) Avient Specialty Formulators Other Specialty / Chemical Companies Source: Peer data per Bloomberg as of February 13, 2023 Note: Avient reflects 2023 estimated revenue of $3,450 and estimated run-rate CAPEX of $110M. 30 3 2 3 3 4 4 3 4 5 5 5 6 7 7 A vi e n t K W R P P G F U L A V Y R P M F M C H U N H X L C E E C L A S H S C L E M N F R E E C A S H F LOW C O N V E R S I O N Source: Peer data per Bloomberg as of February 13, 2023 Note: Free cash flow conversion calculated as (Adjusted EBITDA – Capex) / Adjusted EBITDA. Avient 2011 and 2018 valuations reflect trailing 12 months EBITDA at December 31 of the respective years. 32 EV / 2023E EBITDA Historic Multiple 6.5 8.3 10.0 15.6 13.9 13.7 12.8 9.5 18.0 17.5 12.3 10.2 9.7 8.8 8.4 5.9 A vi e n t (2 0 1 1 ) A vi e n t (2 0 1 8 ) A vi e n t K W R P P G R P M A V Y F U L H X L E C L F M C A S H S C L H U N E M N C E R A W M AT E R I A L O V E R V I E W 34 RAW MATERIAL 2022 ANNUAL PURCHASES Performance Additives 16% Pigments 12% TiO2 11% Dyestuffs 2% Polyethylene 12% Nylon 6% Polypropylene 6% Styrenic Block Copolymer 5% Other Raw Materials 30% ~40% hydrocarbon based (Grey shaded materials are hydrocarbon based, includes portion of “Other Raw Materials”) Non-hydrocarbon based materials Excludes Avient Protective Materials SEGMENT DATA U.S. & Canada 40% EMEA 37% Asia 18% Latin America 5% 2022 PRO FORMA SEGMENT, END MARKET AND GEOGRAPHY GEOGRAPHY REVENUESEGMENT FINANCIALS Consumer 20% Packaging 24% Industrial 15% Building and Construction 10% Telecommunications 4% Energy 4% Defense 6% END MARKET REVENUE (1) Total company adjusted EBITDA of $592M includes corporate costs $2,355M $402M $1,300M $272M Sales EBITDA Specialty Engineered Materials Color Additives and Inks $592M$3,653M (1) Transportation 9% Healthcare 8% 36 C O L O R , A D D I T I V E S & I N K S 2 0 2 2 R E V E N U E | $ 2 . 4 B I L L I O N US & Canada 34% EMEA 38% Asia 20% Latin America 8% END MARKET REGION 37 Packaging 34% Consumer 21% Healthcare 8% Industrial 15% Transportation 8% Building & Construction 11% Telecommunications 1% Energy 2% S P E C I A L T Y E N G I N E E R E D M A T E R I A L S 2 0 2 2 P R O F O R M A R E V E N U E | $ 1 . 3 B I L L I O N END MARKET US & Canada 52% EMEA 35% Asia 13% REGION 38 Packaging 5% Consumer 19% Healthcare 8%Industrial 16% Transportation 10% Telecommunications 10% Energy 9% Defense 15% Building & Construction 8% Packaging 32% Consumer 27% Healthcare 8% Industrial 14% Building & Construction 5% Telecommunications 3% Energy 1% Defense 1% Asia (18% of sales) Transportation 9% 2 0 2 2 P R O F O R M A AV I E N T R E G I O N A L S A L E S B Y E N D M A R K E T Packaging 27% Consumer 14% Healthcare 5% Industrial 17% Building & Construction 10% Energy 5% Defense 8% EMEA (37% of sales)Transportation 11% Packaging 13% Consumer 24% Healthcare 12% Industrial 15% Building & Construction 13% Energy 5% Defense 5% US & Canada (40% of sales) Transportation 7% Packaging 56% Consumer 23% Healthcare 4% Industrial 7% Building & Construction 4% Telecommunications 1% LATAM (5% of sales) Transportation 5% Telecommunications 3% Telecommunications 6% 39

Purchase price multiple rapidly declining on strength of business and synergy capture 7 $133 $201 2019PF 2022E 7 Clariant Color EBITDA Growth Purchase Price Multiple 10.8x 7.0x 6.4x 2019PF 2021 2022E w/ Full Synergies (1) (1) 11.9% 16.3% 2019PF 2022E EBITDA Margins (1) CLARIANT COLOR: TRANSFORMATIONAL ACQUISITION ($ in millions) (1) Financial information is pro forma to include a full year of Clariant Color business SUNBELT PVC Resins DSS 20 Acquisitions $4.8B Investment $2.7B of Annual Revenue 5 Divestments $2.3B Proceeds TPE PP&S HISTORI C SPECI AL IZATION THROUGH M& A 8 Distribution DSM Protective Materials BOLT-ON AC QUI SITI ON HISTORY 9 Commercial Resources Operating Income ($ in millions) Operating Margins 259 363 At Acquisition 2022E $40 $139 At Acquisition 2022E 9% 22% At Acquisition 2022E Established Acquisitions (> 7 years) + 40% + 248% + 1300 bps I N V E S T T O G R O W S P E C I A LT Y T R A N SF O R M ATI O N T O D A Y 7% 46% 67% 86% 100% 0% 20% 40% 60% 80% 100% 2005 2010 2019 2021 2022 PF % o f A d ju st e d E B IT D A • Commodity JVs • Distribution • Performance Products & Solutions • Specialty Businesses (1) Adjusted EBITDA is EBITDA excluding corporate costs and special items (2) Pro forma for the acquisition of Dyneema® and divestiture of Distribution (1 ) (2) 10 Healthcare 4% Packaging 8% Consumer 10% Building & Construction 43% Industrial 15% Transportation 14% Energy 4% Telecom. 2% 2006 2022 Pro Forma Healthcare 8% Packaging 23% Consumer 21% Building & Construction 10% Industrial 15% Transportation 9% Energy 4% Telecom. 4% Defense 6% END MAR KET F OCUS ON LESS CYCL IC AL I ND USTRI ES 11 14.8% 17.6% 21.0% 2018 2020 2022 PF 1.8% 2006 15.3% 16.2% 17.0% 2018PF 2020PF 2022E CAI 2.7% 2006 SEM SPEC IA LTY EBI TDA MA RGI N EX PANSION 12 • Portfolio transformation accelerates growth in less cyclical, higher margin end markets • Investments in our composites platform continue to drive margin expansion (1) (1) (1) 2018 and 2020 financial information is pro forma to include a full year of Clariant Color acquisition PORTFOLIO EVOLUTION OVER THE YEARS 13 Adj. EBITDA Margins (1) • Focus on organic growth combined with transformative and bolt-on acquisitions • Divested commodity businesses tied to more cyclical end markets • Expanded presence in high growth areas of sustainable solutions, specialty healthcare applications, composites and more resilient end markets 5.4% 11.5% 16.1% 2006 2018 2022PF $142 $408 $585 2006 2018 2022PF 2006 figures exclude joint venture results 14 RETURNING CASH TO SHAREHOLDERS Growing Dividend 0.1 0.1 0.2 0.5 0.6 0.7 0.8 0.9 0.9 1.0 1.0 1.0 11 12 13 14 15 16 17 18 19 20 21 22 0.16 0.20 0.26 0.34 0.42 0.50 0.58 0.72 0.79 0.81 0.85 0.95 0.99 11 12 13 14 15 16 17 18 19 20 21 22 23 ~$1Bn REPURCHASED OVER LAST 11 YEARS ~$550MM PAID OVER LAST 11 YEARS Dividends Share Repurchases Cumulative Buybacks $ B n $ p e r sh a re $2.95 2022 PRO FORMA ADJUSTED EPS Earnings Growth Expanding Profitability $0.15 $1.09 $2.08 $2.67 $2.95 2009 2012 2015 2018 2022PF T H I R D Q U A R T E R 2 0 2 2 R E S U L T S $110 $119 2021 2022 $0.61 $0.59 2021 2022 Q3 2022 PERFORMANCE ( T O TA L C O M PA N Y C O N T. Sales EBITDA Specialty Engineered Materials Color Additives and Inks $585M$3,635M (1) Transportation 9% Healthcare 8% 23 C O L O R , A D D I T I V E S & I N K S 2 0 2 2 R E V E N U E | $ 2 . 3 B I L L I O N US & Canada 35% EMEA 40% Asia 20% Latin America 5% END MARKET REGION 24 Packaging 33% Consumer 22% Healthcare 9% Industrial 15% Transportation 8% Building & Construction 11% Telecommunications 1% Energy 1% Figures represent 2022 full year estimates S P E C I A L T Y E N G I N E E R E D M A T E R I A L S 2 0 2 2 P R O F O R M A R E V E N U E | $ 1 . 3 B I L L I O N END MARKET US & Canada 50% EMEA 35% Asia 15% REGION 25 Figures represent 2022 full year estimates Packaging 5% Consumer 19% Healthcare 8%Industrial 16% Transportation 10% Telecommunications 10% Energy 9% Defense 15% Building & Construction 8% Packaging 31% Consumer 28% Healthcare 8% Industrial 13% Building & Construction 5% Telecommunications 3% Energy 2% Defense 1% Asia (20% of sales) Transportation 9% 2 0 2 2 P R O F O R M A AV I E N T R E G I O N A L S A L E S B Y E N D M A R K E T Packaging 29% Consumer 13% Healthcare 5% Industrial 17% Building & Construction 11% Energy 5% Defense 7% EMEA (35% of sales) Transportation 10% Packaging 14% Consumer 23% Healthcare 11% Industrial 15% Building & Construction 12% Energy 5% Defense 7% US & Canada (40% of sales) Transportation 7% Packaging 49% Consumer 22% Healthcare 8% Industrial 9% Building & Construction 6% Telecommunications 1% LATAM (5% of sales) Transportation 5% Telecommunications 3% Telecommunications 6% Figures represent 2022 full year estimates Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.

Trilliant™ HC high performance formulations were developed for specific healthcare enclosure needs, including: • Chemical resistance to common disinfectants • UL 94 ratings of 5VA at 3.0, V-0 at 1.5 mm & V-1 at 0.75 mm • Retained color aesthetics after chemical exposure • Ability to utilize existing PC/PET & COPE tooling Tested using an adaptation from ASTM D543 for environmental stress cracking resistance (ESCR), 15 bars of each material were placed into jigs at 1% and 2% strain. Currently, concerns over healthcare-associated infections (HAIs) have led many medical facilities to respond by disinfecting equipment surfaces more frequently using harsher disinfectants. AVIENT SOLUTIONS PROVIDE DISINFECTANT DURABILITY PROGRAM BULLETIN Contact Avient today to learn how our innovative healthcare solutions can prevent chemical related stress cracking, premature field failures, and component discoloration while mitigating the potential risk of complaints or claims.

MEDICAL DEVICE DISINFECTION—HOW TO PREVENT CRACKING AND CRAZING Understanding polymer performance is key to minimizing disinfectant-related failures DISINFECTANT-RELATED DAMAGE ON POLYMER HOUSINGS Strong chemicals used to reduce hospital- acquired infections can damage equipment and result in material failures, such as: • Stress cracking • Crazing • Discoloration CHEMICAL RESISTANCE REQUIREMENTS VARY BY ENVIRONMENT • Patient/exam rooms • Operating and radiology rooms • Reception areas • Home (patient equipment & devices) Healthcare devices must perform flawlessly in a myriad of challenging environments and engineers must be certain their devices can withstand increasingly potent disinfectants, which have begun to outstrip the performance of traditional polymers. When it comes to material selection and options, you need a strong partner that understands both polymers and the demands of the healthcare environment. Avient has served the healthcare industry for decades with a full portfolio of innovative materials and services.

Trilliant™ HC Healthcare Thermoplastics Glass-filled Polyketone Formulations This Trilliant™ HC glass-filled (GF) series consists of specialty engineered, polyketone (PK) thermoplastics. In addition to these high-performance characteristics, this healthcare portfolio offers a reduced carbon footprint over the product life cycle because PK production emits up to 61 percent less carbon dioxide (CO2) than nylon. KEY CHARACTERISTICS • Excellent chemical resistance • Low moisture uptake • Comparable dimensional stability to nylon • Reinforced with 10–33% glass fill • High impact and wear resistance • Eco-conscious alternative to PA66 and PA6 MARKETS & APPLICATIONS Whether using a standard or customized formulation, the PK-based Trilliant grades provide a high-performing, cost-competitive, and more eco-conscious alternative to competitive materials found in biopharmaceutical processing, hospital settings, and home healthcare applications.